Histone deacetylase inhibition differentially attenuates cue-induced reinstatement: An interaction of environment and acH3K9 expression in the dorsal striatum.


Journal

Behavioral neuroscience
ISSN: 1939-0084
Titre abrégé: Behav Neurosci
Pays: United States
ID NLM: 8302411

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 26 7 2019
medline: 6 2 2020
entrez: 26 7 2019
Statut: ppublish

Résumé

Substance use disorder is driven by complex gene-environment interactions. Epigenetic histone regulation is a significant contributor to several behavioral phenotypes of drug abuse. The primary epigenetic mechanisms that drive drug taking and drug seeking are still being investigated, and it is unclear how environmental conditions alter epigenetic histone acetylation to change behaviors geared toward drug reward. This study examined the effects of environmental condition on amphetamine self-administration, and whether drug-taking and drug-seeking behaviors could be influenced through inhibition of an epigenetic regulator, histone deacetylase (HDAC). Male rats reared for 30 days in enriched (EC), isolated (IC), or standard conditions (SC) prior to amphetamine (0.03, 0.05, 0.1 mg/kg/infusion, IV) self-administration, extinction, and reinstatement sessions. The HDAC inhibitor, Trichostatin A (TsA; 0.3 mg/kg, IV), was injected 30 min prior to operant sessions. After amphetamine-induced reinstatement (0.25 mg/kg, subcutaneous [s.c.]), tissue was extracted for Western blot analyses of acetylated histone H3 lysine 9 (acH3K9) in the nucleus accumbens (NAc) and dorsal striatum (DSt). While TsA did not significantly affect amphetamine self-administration or extinction, TsA decreased cue-, but not drug-induced reinstatement in IC rats only. In the DSt, but not in the NAc, IC rats exhibited significantly less acH3K9 expression than EC and SC rats, irrespective of TsA treatment. HDAC inhibition decreases cue-induced reinstatement of amphetamine seeking in IC rats. While IC rats exhibit less acH3K9 expression in the DSt, future studies are needed to elucidate the critical epigenetic factors that drive substance abuse, particularly in vulnerable populations. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Identifiants

pubmed: 31343201
pii: 2019-42428-001
doi: 10.1037/bne0000333
pmc: PMC6722001
mid: NIHMS1043114
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
Histones 0
Amphetamine CK833KGX7E
Histone Deacetylases EC 3.5.1.98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

478-488

Subventions

Organisme : American Psychological Association
Organisme : NIDA NIH HHS
ID : R15 DA035435
Pays : United States

Références

Neuroscience. 2000;100(4):749-68
pubmed: 11036209
Psychopharmacology (Berl). 2001 May;155(3):278-84
pubmed: 11432690
Mol Biotechnol. 2002 Jan;20(1):99-106
pubmed: 11876304
Psychopharmacology (Berl). 2002 Aug;162(4):373-8
pubmed: 12172690
Neuron. 2004 Jun 24;42(6):947-59
pubmed: 15207239
Neuron. 2004 Jun 24;42(6):961-72
pubmed: 15207240
J Neurosci. 2005 Sep 21;25(38):8665-70
pubmed: 16177034
Life Sci. 2006 Jun 13;79(3):281-6
pubmed: 16460767
Nat Neurosci. 2006 Apr;9(4):519-25
pubmed: 16501568
Behav Pharmacol. 2006 Nov;17(7):597-604
pubmed: 17021392
Nature. 2007 May 10;447(7141):178-82
pubmed: 17468743
Behav Brain Res. 2007 Jul 19;181(1):76-84
pubmed: 17477979
Neuropsychopharmacology. 2008 May;33(6):1413-25
pubmed: 17712353
Neuron. 2007 Nov 8;56(3):517-29
pubmed: 17988634
Neurosci Biobehav Rev. 2008 Aug;32(6):1087-102
pubmed: 18423591
J Neurosci. 2008 Sep 17;28(38):9342-8
pubmed: 18799668
Physiol Behav. 1991 Jun;49(6):1107-18
pubmed: 1896492
Biol Psychiatry. 2009 Feb 1;65(3):191-7
pubmed: 19006788
Behav Pharmacol. 2008 Dec;19(8):777-85
pubmed: 19020412
Pharmacol Biochem Behav. 2009 May;92(3):377-82
pubmed: 19463254
Neuroscience. 2009 Sep 29;163(1):1-8
pubmed: 19531374
Biol Psychiatry. 2010 Jan 1;67(1):28-35
pubmed: 19709647
Neuropsychopharmacology. 2009 Dec;34(13):2642-54
pubmed: 19727068
Neuropsychopharmacology. 2009 Dec;34(13):2767-78
pubmed: 19741591
Biol Psychiatry. 2010 Jan 1;67(1):36-43
pubmed: 19765687
Neuropsychopharmacology. 2009 Dec;34(13):2619-20
pubmed: 19794404
Neuropsychopharmacology. 2010 Mar;35(4):913-28
pubmed: 20010550
J Neurochem. 2010 Apr;113(1):236-47
pubmed: 20132486
Curr Psychiatry Rep. 2010 Apr;12(2):145-53
pubmed: 20425300
Neurosci Lett. 2011 Apr 15;493(3):122-6
pubmed: 21335060
Am J Transl Res. 2011 Feb;3(2):166-79
pubmed: 21416059
Behav Brain Res. 2011 Sep 12;222(1):246-64
pubmed: 21504762
Curr Neuropharmacol. 2011 Mar;9(1):21-5
pubmed: 21886555
Psychopharmacology (Berl). 2011 Nov;218(1):293-301
pubmed: 21887496
Neurobiol Dis. 2012 Jan;45(1):488-98
pubmed: 21964251
Nat Rev Neurosci. 2011 Oct 12;12(11):623-37
pubmed: 21989194
J Neurosci. 2011 Dec 7;31(49):17835-47
pubmed: 22159099
PLoS One. 2012;7(3):e34236
pubmed: 22470541
Neuropsychopharmacology. 2012 Aug;37(9):2109-20
pubmed: 22534624
Behav Pharmacol. 2012 Oct;23(7):650-7
pubmed: 22914073
Annu Rev Pharmacol Toxicol. 2013;53:311-30
pubmed: 23294310
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52
pubmed: 23297220
Neurosci Lett. 2013 Mar 1;536:47-51
pubmed: 23313592
Pharmacol Biochem Behav. 2013 May;106:109-16
pubmed: 23454534
Neuropharmacology. 2014 Jan;76 Pt B:259-68
pubmed: 23643695
ILAR J. 2012;53(3-4):279-88
pubmed: 23744967
PLoS One. 2013 Aug 14;8(8):e71323
pubmed: 23967191
Biol Psychiatry. 2014 Jul 1;76(1):47-56
pubmed: 24239129
Exp Clin Psychopharmacol. 2014 Jun;22(3):257-65
pubmed: 24467371
Subst Abuse Rehabil. 2013 Feb 08;4:29-43
pubmed: 24648786
Behav Brain Res. 2014 Aug 15;270:151-8
pubmed: 24821405
Behav Pharmacol. 2014 Sep;25(5-6):341-51
pubmed: 25003947
Alcohol Clin Exp Res. 2014 Sep;38(9):2377-86
pubmed: 25130590
Epigenetics. 2015;10(7):574-80
pubmed: 26023847
Psychopharmacology (Berl). 2015 Oct;232(20):3741-52
pubmed: 26211759
Drug Alcohol Depend. 2016 Jun 01;163:195-201
pubmed: 27125660
J Addict Prev. 2015;2015(Suppl 1):null
pubmed: 27453897
Cell Mol Life Sci. 2017 Aug;74(15):2735-2747
pubmed: 28255755
J Biol Chem. 2017 Sep 1;292(35):14456-14472
pubmed: 28717009
Handb Clin Neurol. 2018;148:747-765
pubmed: 29478612
Alcohol Clin Exp Res. 2018 Nov;42(11):2160-2171
pubmed: 30103280
Child Dev. 1987 Jun;58(3):539-59
pubmed: 3038480
Psychopharmacology (Berl). 2019 Jan;236(1):517-529
pubmed: 30488346
Brain Res. 2019 Jun 1;1712:63-72
pubmed: 30716289
Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):397-405
pubmed: 7667360
Dev Psychobiol. 1977 Mar;10(2):123-32
pubmed: 838157
Pharmacol Biochem Behav. 1998 Apr;59(4):859-72
pubmed: 9586842

Auteurs

David L Arndt (DL)

Department of Psychological Sciences.

Thomas J Wukitsch (TJ)

Department of Psychological Sciences.

Erik J Garcia (EJ)

Department of Psychological Sciences.

Mary Cain (M)

Department of Psychological Sciences.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH